Catherine Thiéblemont

35.7k citations
420 papers · 14.3k indexed · 4 hit papers · h-index 66
Topics
Lymphoma Diagnosis and Treatment (299 papers)Chronic Lymphocytic Leukemia Research (152 papers)CAR-T cell therapy research (117 papers)

In The Last Decade

Catherine Thiéblemont

393 papers receiving 14.1k citations

Hit Papers

Long-term outcome of patients in the LNH-98.5 trial, the ...201020262015202020102016202220252505007501000

Peers

Catherine Thiéblemont
Comparison fields: 5 of 132
  • Pathology and Forensic Medicine 9.9k
  • Oncology 7.0k
  • Genetics 4.4k
  • Neurology 2.4k
  • Molecular Biology 2.0k
Replace Jonathan W. Friedberg with:
Jonathan W. Friedberg United States
Franco Cavalli Switzerland
Michele Ghielmini Switzerland
Emanuele Zucca Switzerland
Hervé Tilly France
Joachim Yahalom United States
Brian K. Link United States
Massimo Federico Italy
Won Seog Kim South Korea
Nancy L. Bartlett United States
Catherine Thiéblemont relative to Jonathan W. Friedberg United States Jonathan W. Friedberg's profile →
Citations per field
00.5×11×
Jonathan W. Friedberg · 1×
Citations per year

Countries citing papers authored by Catherine Thiéblemont

Since Specialization
Citations

This map shows the geographic impact of Catherine Thiéblemont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Thiéblemont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Thiéblemont more than expected).

Fields of papers citing papers by Catherine Thiéblemont

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Thiéblemont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Thiéblemont. The network helps show where Catherine Thiéblemont may publish in the future.

Co-authorship network of co-authors of Catherine Thiéblemont

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Thiéblemont. A scholar is included among the top collaborators of Catherine Thiéblemont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Thiéblemont. Catherine Thiéblemont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 0
4 4
5 2
6 29
7 12
8 19
9 4
10 16
11 20
12 17
13 5
14 1
15 42
16 148
17 157
18 216
19
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adultebreakdown →
1071
20 161

About Catherine Thiéblemont

Catherine Thiéblemont is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 420 papers that have together received 14.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (299 papers), Chronic Lymphocytic Leukemia Research (152 papers) and CAR-T cell therapy research (117 papers). The work is most often cited by research in Pathology and Forensic Medicine (9.9k citations), Genetics (4.4k citations) and Oncology (7.0k citations). Catherine Thiéblemont has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Bertrand Coiffier, Gilles Salles, Pascale Felman, Charles Dumontet, Hervé Tilly, Franck Morschhauser, Françoise Berger, Emanuele Zucca, Evelyne Callet‐Bauchu and Fadhela Bouafia. Their work appears in journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026